global view constructed of white lines
brain tumor clinical trials banner
January 4, 2017

Clinical Trials Round-Up: January 2017

by Zara Jethani

We have added a new clinical trial and a dose expansion cohort to our roster of brain tumor clinical trials at the Pacific Neuroscience Research Center at Pacific Neuroscience Institute.


New Trial
Triphase MRZ-112 (NCT02903069): Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer. Download pdf flyer

Dose-Expansion Cohort
Triphase MRZ-108 (NCT02330562): Phase 2 Trial of Single Agent Marizomib in Progressive or Recurrent Grade IV Malignant Glioma. Download pdf flyer


Primary Brain Tumor

AbbVie / RTOG (NCT02573324): A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification. Download pdf flyer

Boehringer Ingelheim (NCT02423525): A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain Cancer. Download pdf flyer

Inspyr Therapeutics (NCT02876003): Efficacy, Safety and CNS Exposure of G-202 in Patients with PSMA-Positive Recurrent or Progressive Glioblastoma. Download pdf flyer

ImmunoCellular (NCT02546102): A Phase III Randomized Double-Blind, Controlled Study of ICT-107 with Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma following Resection and Concomitant TMZ Chemoradiotherapy. Download pdf flyer

Nativis (NCT02296580): A Feasibility Study of the Nativis Voyager System in Patients With Recurrent Glioblastoma Multiforme (GBM). Download pdf flyer

Orbus Therapeutics (NCT02796261): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy. Download pdf flyer

Brain Metastases

Boehringer Ingelheim (NCT02423525): A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain CancerDownload pdf flyer

Eli Lilly and Company (NCT02308020): A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma. Download pdf flyer 

EpiCentRX (NCT02215512): Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases (BRAINSTORM). Download pdf flyer

Kadmon (NCT02616393): Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases. Download pdf flyer

Achal S. Achrol, MD
Garni Barkhoudarian, MD
Daniel Kelly, MD
Santosh Kesari MD, PhD, FANA, FAAN
Steven O’Day, MD

Clinical Trial Team:
Najee Boucher, CRA  |  310-582-7460
Jaya M. Gill, RN, BSN  |  310-582-7437
Annie Heng, RN, BSN   |  310-582-7457
Tiffany Juarez, PhD
Marlon Garzo Saria, PhD, RN, AOCNS, FAAN

For more information, please contact the Neuro-oncology Clinical Trial Team at:
phone: 310-829-8265

About the Author

Zara Jethani, MS, MBA

Zara Jethani

Zara is the marketing director at Pacific Neuroscience Institute. Her background is in molecular genetics research and healthcare marketing. In addition, she is a graphic designer with more than 20 years experience in the healthcare, education and entertainment industries.

Last updated: November 13th, 2019